Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily versus twice-daily oral mesalazine plus rectal mesalazine for active ulcerative colitis
2008-000045-59Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Remission at 8 weeks by UC-DAI. Started Apr 2008; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2008-000045-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000045-59.